Theriva™ biologics announces u.s. fda guidance on design of phase 3 study of vcn-01 for the treatment of metastatic pancreatic cancer

Rockville, md., dec. 05, 2024 (globe newswire) -- theriva™ biologics (nyse american: tovx), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent type d meeting with the u.s. food and drug administration (fda) to obtain guidance on the design of a phase 3 clinical study of lead clinical candidate vcn-01 in combination with standard-of-care chemotherapy for the treatment of metastatic pancreatic adenocarcinoma (pdac). the company recently announced the completion of target enrollment into the multinational virage phase 2b clinical study evaluating intravenous vcn-01 in combination with gemcitabine/nab-paclitaxel as a first line therapy for pdac patients.
TOVX Ratings Summary
TOVX Quant Ranking